Moderna said Wednesday that its COVID-19 vaccine candidate
mRNA-1273 produced an immune response in older adult volunteers who were given
two doses of the vaccine in an early-stage trial. The participants had higher
levels of antibodies to the novel coronavirus two months after receiving the
shots than patients who had been infected and recovered.
No comments:
Post a Comment